We are live on ! Find out more
NWBO

Northwest Biotherapeutics
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

7 hedge funds and large institutions have $42K invested in Northwest Biotherapeutics in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

406% more capital inflows, than outflows

Capital inflows: $5.4K | Capital outflows: $1.07K

40% more funds holding

Funds holding: 5 → 7 (+2)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
7
Holders Change
+2
Holders Change %
+40%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

NWBO Hedge Fund Activity: Q2 2019 in Review

7 of the 4,627 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics (NWBO) for Q2 2019, worth a combined $42K — up 7.7% from $39K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new NWBO positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Opus Capital Group, opening a new position worth an estimated $3K. The largest seller was CAPTRUST Financial Advisors, cutting an estimated $1.07K.

  • 7 institutional investors held Northwest Biotherapeutics (NWBO) as of Q2 2019, up from 5 in Q1 2019.
  • Funds reported $42K of Northwest Biotherapeutics stock for Q2 2019, up 7.7% quarter-over-quarter.
  • 2 funds opened new Northwest Biotherapeutics positions in Q2 2019 and 0 closed out, a net change of +2 holders.
  • The largest Northwest Biotherapeutics buyer in Q2 2019 was Opus Capital Group, an estimated $3K added.
  • The largest Northwest Biotherapeutics seller in Q2 2019 was CAPTRUST Financial Advisors, an estimated $1.07K sold.

Based on aggregated 13F filings for Q2 2019.